The therapeutic monoclonal antibody market
By D. Ecker, S. D. Jones, H. Levine. mAbs, 2015
1,210 citations recorded by the source corpus.
Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.
Subfields: Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/f8a4f701132782d5b18e10118d4fb3ea2b67f631
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Andrew Leaver-Fay
- Brian Kuhlman
- David Baker
- Tanja Kortemme
- Jeffrey J. Gray
- I. Samish
- Jens Meiler
- Ron Jacak
Citations in the corpus
- Computationally Designed Bispecific Antibodies Using Negative State Repertoires (2016, background): “…or humanized/ fully human IgG antibodies have demonstrated their utility in the treatment of many different diseases with >40 approved and 100s in clinical trials (Ecker et al., 2015) and their advantageous properties (stability, solubility, manufacturability, pharmacokinetics) are well documented.”